financetom
Business
financetom
/
Business
/
RoundTable Healthcare Partners Announces Sale of Renaissance Lakewood, LLC
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RoundTable Healthcare Partners Announces Sale of Renaissance Lakewood, LLC
Oct 13, 2025 7:10 AM

LAKE FOREST, Ill., Oct. 13, 2025 /PRNewswire/ -- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company Renaissance Lakewood ("Renaissance") has entered into a definitive agreement to be acquired by LTS LOHMANN Therapie-Systeme AG ("LTS"). LTS is a pharmaceutical technology company developing and manufacturing innovative drug delivery systems and is located in Andernach, Germany. Terms of the transaction were not disclosed.

Renaissance is a premier contract development and manufacturing organization ("CDMO") focused on nasal and injectable pharmaceutical products, including unit-dose, bi-dose, and multi-dose nasal sprays as well as small-volume parenteral fill-finish vials. Renaissance was founded by RoundTable through the acquisition of two leading CDMOs, Confab Laboratories in 2010 and DPT Laboratories in 2012. Following the 2016 divestiture of its topicals division to Mylan N.V., the company has focused on advancing its intranasal and injectable dosage platforms. Through significant investments in leadership and talent, research & development, and state-of-the-art infrastructure, Renaissance has evolved into a leading, fully integrated CDMO and serves as a partner to both established and emerging pharmaceutical and biotech customers.

Pierre Frechette, Managing Partner of RoundTable and Chairman of Renaissance, commented, "On behalf of RoundTable, I would like to thank our exceptional management team and talented employees of Renaissance for creating a high-quality, differentiated business. We believe LTS will be a strong long-term partner to support the business moving forward."

Serge Maltais, President & CEO of Renaissance added, "Renaissance has benefited tremendously from RoundTable's support and guidance. Together, we've grown and transformed the company into one of the industry leaders that it is today. We thank RoundTable and now look forward to an exciting future as part of LTS."

This transaction is expected to close in November 2025, subject to regulatory approvals.

Sidley Austin LLP acted as exclusive legal advisor to Renaissance and RoundTable in this transaction.

About RoundTable Healthcare Partners

RoundTable Healthcare Partners, based in Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the healthcare industry. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise. RoundTable has established a successful track record of working with owner/founders, family companies, management teams, entrepreneurs, and corporate partners who share a vision and believe in the value creation potential of its partnership model. RoundTable has raised $4.25 billion in committed capital, including six equity funds totaling $3.65 billion and three subordinated debt funds totaling $600 million. More information about RoundTable Healthcare Partners can be found at www.roundtablehp.com.

View original content:https://www.prnewswire.com/news-releases/roundtable-healthcare-partners-announces-sale-of-renaissance-lakewood-llc-302582062.html

SOURCE RoundTable Healthcare Partners

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gap Stock Soars On Q1 Earnings Beat, Retailer Raises Guidance Following Strong Performance
Gap Stock Soars On Q1 Earnings Beat, Retailer Raises Guidance Following Strong Performance
May 30, 2024
Gap Inc ( GPS ) shares are rising in extended trading Thursday on the heels of the company’s first-quarter financial results. Q1 Revenue: $3.39 billion, versus estimates of $3.29 billion Q1 EPS: 41 cents, versus estimates of 14 cents Comparable sales were up 3% year-over-year. Store sales were up 3%, while online sales jumped 5%. Merchandise margin increased 340 basis...
HashiCorp Fiscal Q1 Swings to Non-GAAP Earnings; Revenue Increases
HashiCorp Fiscal Q1 Swings to Non-GAAP Earnings; Revenue Increases
May 30, 2024
05:03 PM EDT, 05/30/2024 (MT Newswires) -- HashiCorp ( HCP ) reported fiscal Q1 non-GAAP earnings Thursday of $0.05 per diluted share, compared with a loss of $0.07 a year earlier. Analysts surveyed by Capital IQ expected a loss of $0.01. Revenue in the quarter ended April 30 rose to $160.6 million from $138 million a year earlier. Analysts surveyed...
Gilead's Trodelvy fails to meet main goal in late-stage study
Gilead's Trodelvy fails to meet main goal in late-stage study
May 30, 2024
May 30 (Reuters) - Gilead Sciences ( GILD ) said on Thursday its drug Trodelvy, tested in patients with bladder cancer who previously received chemotherapy, did not meet the main goal of a late-stage study. ...
Nordstrom Reports Fiscal Q1 Adjusted Loss, Revenue Rises; 2024 Outlook Reaffirmed -- Shares Fall After Hours
Nordstrom Reports Fiscal Q1 Adjusted Loss, Revenue Rises; 2024 Outlook Reaffirmed -- Shares Fall After Hours
May 30, 2024
05:12 PM EDT, 05/30/2024 (MT Newswires) -- Nordstrom ( JWN ) reported a fiscal Q1 adjusted net loss late Thursday of $0.24 per diluted share, compared with earnings of $0.07 per share a year earlier. Analysts polled by Capital IQ expected a loss of $0.07. Revenue for the quarter ended May 4 rose to $3.34 billion from $3.18 billion a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved